Overview
Study in Subjects With Small Primary Choroidal Melanoma
Status:
Completed
Completed
Trial end date:
2021-01-26
2021-01-26
Target enrollment:
0
0
Participant gender:
All
All
Summary
The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.Phase:
Phase 1/Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Aura Biosciences
Criteria
Inclusion Criteria:- Diagnosis of choroidal melanoma
Exclusion Criteria:
- Have known contraindications or sensitivities to the study drug